Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Paul Gerard RichardsonAlbert OriolAlessandra LaroccaJoan BladéMichele CavoPaula Rodriguez-OteroXavier LeleuOmar NadeemJohn W HiemenzHani HassounCyrille TouzeauAdrián AlegreAgne PanerChristopher MaiselAmitabha MazumderAnastasios RaptisJan S MorebKenneth C AndersonJacob P LaubachSara ThuressonMarcus ThuressonCatriona ByrneJohan HarmenbergNicolaas A BakkerMaría-Victoria Mateosnull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Melflufen plus dexamethasone showed clinically meaningful efficacy and a manageable safety profile in patients with heavily pretreated RRMM, including those with triple-class-refractory and extramedullary disease.